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Abstract
Background: Toll-like receptors (TLR) and related downstream signaling pathways of innate
immunity have been implicated in the pathogenesis of Plasmodium falciparum malaria. Because of
their potential role in malaria pathogenesis, polymorphisms in these genes may be under selective
pressure in populations where this infectious disease is endemic.
Methods: A post-PCR Ligation Detection Reaction-Fluorescent Microsphere Assay (LDR-FMA)
was developed to determine the frequencies of TLR2, TLR4, TLR9, MyD88-Adaptor Like Protein (MAL)
single nucleotide polymorphisms (SNPs), and TLR2 length polymorphisms in 170 residents of two
regions of Kenya where malaria transmission is stable and high (holoendemic) or episodic and low,
346 residents of a malaria holoendemic region of Papua New Guinea, and 261 residents of North
America of self-identified ethnicity.
Results: The difference in historical malaria exposure between the two Kenyan sites has
significantly increased the frequency of malaria protective alleles glucose-6-phoshpate dehydrogenase
(G6PD) and Hemoglobin S (HbS) in the holoendemic site compared to the episodic transmission site.
However, this study detected no such difference in the TLR2, TLR4, TLR9, and MAL allele
frequencies between the two study sites. All polymorphisms were in Hardy Weinberg Equilibrium
in the Kenyan and Papua New Guinean populations. TLR9 SNPs and length polymorphisms within
the TLR2 5' untranslated region were the only mutant alleles present at a frequency greater than
10% in all populations.
Conclusion: Similar frequencies of TLR2, TLR4, TLR9, and MAL genetic polymorphisms in
populations with different histories of malaria exposure suggest that these innate immune pathways
have not been under strong selective pressure by malaria. Genotype frequencies are consistent
with Hardy-Weinberg Equilibrium and the Neutral Theory, suggesting that genetic drift has
influenced allele frequencies to a greater extent than selective pressure from malaria or any other
infectious agents in these populations.
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Every year 350–500 million cases of malaria occur world-
wide, and up to 2.5 million of these individuals are esti-
mated to die, mainly from neurologic complications,
severe anaemia or respiratory distress due to Plasmodium
falciparum [1]. The burden of malaria mortality now and
in recent human evolutionary history has been greatest in
children under the age of five years, consistent with the
notion that malaria has had a powerful effect on selection
of the human genome. Indeed, based on observations of
the geographic overlap between malaria endemicity and
the frequency of erythroid variants such as thalassaemia,
Haldane hypothesized in the mid 20th century that such
polymorphisms were under selective pressure, because
they were protective against severe malaria infection and
thereby increased the reproductive fitness of individuals
living in malaria endemic areas [2,3].
Toll-like receptors are innate immune receptors that
bind to conserved structural motifs expressed by micro-
bial pathogens. TLR2, TLR4, TLR9, and downstream sig-
naling pathways of these proteins have recently been
implicated in human malaria pathogenesis [4-6]. TLR2
is expressed on the cell surface, where it is activated by
bacterial lipopeptides and fungal and Mycoplasma lig-
ands [7-9]. Malaria-derived glycosylphosphatidylinosi-
tol (GPI) has been identified as a potential malaria
"toxin" by activating TLR2 signaling [5]. The TLR2 gene
is located on chromosome 4q32 and is comprised of 3
exons, which encode 784 amino acids [10,11]. A 22 bp
insertion/deletion polymorphism (TLR2 Δ22) in the
first untranslated exon was observed to be highly poly-
morphic in a Japanese population but was not associ-
ated with a disease phenotype [12]. A GT dinucleotide
that varies by approximately 12 to 30 repeats (GTn) is
present within the second intron, approximately 100
bp upstream of the translational start site. Repeats of
varying length have been associated with susceptibility
to tuberculosis, reversal reactions in leprosy, and color-
ectal cancer [13-15]. Shorter repeats are associated with
reduced TLR2 reporter activity and TLR2 surface expres-
sion in vitro [13]. A non-synonymous SNP in the third
exon of TLR2, Arg753Gln, is associated with suscepti-
bility to tuberculosis [16], and presumably because of
its location in the intracellular domain, abolishes
downstream signaling in vitro [17]. TLR4 is expressed
on the cell surface and is activated by bacterial lipopol-
ysaccharide [18,19]. Plasmodium falciparum GPI may
weakly activate TLR4 [5]. The gene is on chromosome
9q32-q33, consists of 4 exons, and spans approxi-
mately 19 kb [10,20]. Two non-synonymous TLR4
SNPs (Asp299Gly and Thr399Ile) are in the extracellu-
lar domain, and commonly co-segregate in European
Caucasian but not in African populations [21,22].
These SNPs have been associated with various infec-
tious and inflammatory diseases (reviewed in [22]).
Ghanaian children with the Asp299Gly and Thr399Ile
alleles had an increased risk of severe malaria [4]. These
TLR4 mutations confer a hyporesponsive phenotype in
vitro in some studies, [23] but not in others [22,24].
TLR9 is expressed in endosomal compartments, where
it binds to and is activated by bacterial DNA with
unmethylated CpG motifs [25,26]. Malaria haemozoin
and/or parasite DNA have been identified as potential
TLR9 ligands [27,28]. TLR9 spans 5 kb on chromosome
3p21.3, consists of 2 exons, and encodes 1028 amino
acids [29]. Three TLR9 SNPs are present at approxi-
mately 15% or greater allele frequency in North Ameri-
can populations [30]. Two of these SNPs, -1486T/C and
-1237T/C, are located within the promoter; 1174G/A is
in the intron. TLR9 -1237 T/C has been associated with
susceptibility to Crohn's Disease, atopic eczema, and
asthma [31-33]. Both TLR4 Asp299Gly and TLR9 -
1486T/C were associated with low birth weight and
maternal anaemia in a malaria endemic population
[34]. MAL (also known as Toll-Interleukin-1 Receptor
domain-containing Adaptor Protein, TIRAP) is a down-
stream adaptor protein common to both the TLR2 and
TLR4 signaling pathways [35,36]. The gene spans 14.5
kb on chromosome 11q24.2, consists of 8 exons, and
encodes a 221 amino acid protein. Individuals hetero-
zygous for a Ser/Leu mutation at amino acid 180 were
reported to be protected from invasive pneumococcal
disease, bacteraemia, malaria, and tuberculosis in an
analysis of several case-control studies conducted in the
UK and sub-Saharan Africa [6]. A subsequent study
found protection against tuberculosis in a population
of Colombians [37], but no protection was revealed in
an analysis comparing tuberculosis cases and controls
from Russia, Ghana, and Indonesia [38]. The Ser to Leu
amino acid change abolishes the ability of TLR2 to
recruit MAL for downstream signaling in vitro [6].
The hypothesis of this study was that the above TLR and
MAL genes are under selective pressure by malaria and
therefore, that the frequencies of the SNPs observed in
these genes would vary significantly among populations
historically and currently exposed to differing levels of
malaria transmission and morbidity. For example, in the
two Kenyan study sites examined here, the frequencies of
sickle cell trait and G6PD deficiency are significantly
greater in the holoendemic site compared to the episodic
transmission site [39], where malaria transmission was
introduced during the first half of the 20th century
[40,41]. To test this hypothesis, residents living in areas
of varying malaria endemicity in sub-Saharan Africa and
Papua New Guinea were genotyped for TLR2, 4, 9, and
MAL polymorphisms. Furthermore, in order to put these
data in the context of innate immune polymorphisms of
populations with no recent history of malaria exposure,
North Americans of self-identified ethnicity were also
analyzed.Page 2 of 10
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Study populations
TLR and MAL genetic polymorphisms were evaluated in
170 individuals from Kenya, 346 individuals from Papua
New Guinea, and 261 North Americans of self identified
ethnicity (total n = 777). Kenyan and Papua New Guinean
study population characteristics in terms of age structure
and malaria infection prevalence are presented in addi-
tional file 1 (table S1). The samples from Kenyans were
collected from residents of two villages in the western part
of the country, Kanyawegi (n = 91) and Kipsamoite (n =
79), as part of an earlier immunoepidemiologic study
[42]. All study participants were asymptomatic with no
malaria-related illness when blood for genotyping was
obtained. Malaria transmission in the lowland area of
Kanyawegi is holoendemic. Annual entomologic inocula-
tion rates may exceed 300 infectious bites per person [43].
Kipsamoite is located in a highland area in the Nandi dis-
trict of Rift Valley Province where malaria transmission is
unstable and characterized by periods with extremely low
malaria infection prevalence [44]. During the course of
this study, uncomplicated malaria cases peaked in Nandi
during the months of May to August, during which time
approximately 200 cases were reported by the Kipsamoite
Health Center [44]. The 346 Papua New Guinean DNA
samples were collected from people of the Urat and Urim
linguistic groups in the Dreikikir district of East Sepik
Province. These individuals were enrolled in a study
examining mass drug administration to eliminate filaria-
sis. During the course of the study, infection rates with
various Plasmodium spp. and P. falciparum asexual densi-
ties were obtained. All individuals were asymptomatic
with no known episodes of severe malaria morbidity.
Malaria transmission is perennial and stable in this area of
Papua New Guinea. The entomologic inoculation rate is
estimated to be 0.9 infectious bites per person per night, a
transmission intensity similar to the holoendemic Kenya
site [45]. Mild malaria in this area has a peak prevalence
in children less than 5 years old, and severe malaria is
most frequently manifested as severe anaemia. DNA from
de-identified North American adults was obtained from
the National Histocompatibility Laboratory, American
Red Cross/University of Maryland Medical System, Balti-
more, MD. Race and ethnicity of the North Americans
were self-identified. The population was heterogeneous –
Asian American (n = 84), Caucasian American of Euro-
pean ancestry (n = 84), and African American (n = 93).
Informed consent, blood sample collection, and genotyp-
ing were performed under protocols approved by the Eth-
ical and Institutional Review Boards for Human
Investigation at the Kenya Medical Research Institute, the
Medical Research Advisory Committee of the Papua New
Guinea Department of Health, and University Hospitals
of Cleveland/Case Western Reserve University.
Polymerase chain reaction (PCR)
Genomic DNA was extracted from blood using the
QIAamp 96 spin blood kit (QIAGEN, Valencia, CA). PCR
was performed using a master mix consisting of 1× PCR
buffer, 125 μM dNTPs, 2.5 mM MgCl2, 125 nM primers,
and 0.8 units Taq polymerase in a reaction volume of 25
μl. PCR primers and amplification conditions are listed in
additional file 2 (table S2). PCR products for SNP detec-
tion were analyzed on a 2% agarose gel prior to LDR-FMA.
TLR2 Δ 22 genotypes were assigned based on size discrim-
ination of PCR products on a 4% agarose gel. TLR2 GTn
genotypes were assigned based on size discrimination of
PCR products run on a 6% polyacrylamide gel as
described elsewhere [46]
Cloning and sequencing
PCR amplification products from local donors were puri-
fied using the QIAquick PCR purification kit (QIAGEN,
Valencia, CA). Purified PCR products were sent to MWG
Biotech, High Point, NC for sequencing. Sequences were
analyzed using the Sequencher software (Gene Codes
Corporation, Ann Arbor, MI). Sequenced DNA templates
were subjected to PCR and used in the LDR-FMA as posi-
tive controls.
SNP genotyping
PCR products were analyzed in a LDR-FMA divided into 3
steps: (1) ligation of oligonucleotides to the SNP, (2) Flex-
MAP microsphere hybridization, and (3) detection using
the Bioplex suspension array system, which includes a flu-
orescence reader and the Bio-Plex Manager analytical soft-
ware (Bio-Rad Laboratories, Hercules, CA). This
procedure is described in detail elsewhere [47]. Conserved
and allele-specific probe sequences are listed in additional
file 3 (table S3).
A multiplex assay was used for simultaneous detection of
TLR2, TLR9, and MAL SNPs. TLR4 SNPs were evaluated in
a separate multiplexed LDR. Equal volumes of each PCR
product were mixed, and 1 μl was added to the LDR. Con-
ditions for the LDR step of this assay are described else-
where [47].
Statistical analysis
Mean Fluorescence Intensity (MFI) values were used to
calculate the allelic ratio for each SNP by dividing the
allele-specific MFI value by the sum of the MFI values for
that SNP (allele A/A+B = An, and allele B/A+B = Bn), where
A and B are the 2 alleles of a SNP. To be homozygous for
a particular allele, the ratio must be > 0.75. To be hetero-
zygous, the ratio of the 2 alleles must be between 0.25 and
0.75. Consequently, an allele included in a ratio of < 0.25
is considered not present. Normalized values for An and
Bn were divided, and the quotient was log-transformed.
The mean and 95% confidence interval (CI) of the log-Page 3 of 10
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in this study are presented in additional file 4 (table S4).
Allele (or haplotype) and genotype (diplotype) frequen-
cies were calculated for the different polymorphisms, the
Hardy-Weinberg exact test (estimation of p-values by the
Markov chain method), and the Ewens-Watterson
homozygosity test was performed for each population
using Arlequin version 3.01 http://cmpg.unibe.ch/soft
ware/arlequin3. Differences in allele frequencies among
study groups were determined by chi-square analysis
using SPSS for Windows (version 13.0). A p-value < 0.05
was considered to be significant. Statistical comparisons
of allele frequencies were made between the following
groups; Kenya malaria holoendemic vs. Kenya episodic
transmission: each of the Kenyan study populations vs.
African American, Kenya holoendemic vs. Papua New
Guinea holoendemic, and Papua New Guinea holoen-
demic vs. Asian Americans. Linkage disequilibrium analy-
sis was performed using SHEsis [48].
Results
Table 1 describes the mutant allele frequencies for the
TLR2, TLR4, TLR9, and MAL SNPs, TLR2 Δ22, and TLR2
GTn polymorphisms in the populations from Kenya,
Papua New Guinea, and North America.
TLR2 polymorphisms
The TLR2 Δ22 polymorphism in the 5' untranslated
region was present in all populations examined at an
allele frequency >10%. The lowest value was in Papua
New Guineans (13.1%), compared with 32.6% for the
Kenyan episodic transmission site. Although the holoen-
demic Kenyan and Papua New Guinea sites have similar
malaria transmission intensities, this allele was signifi-
cantly less common in Papua New Guinea compared to
the Kenya holoendemic site (p < 0.001). Allele frequen-
cies were similar for Kenyan study participants from the
holoendemic and episodic transmission sites.
The GTn repeat in the 5' untranslated region of TLR2 was
highly polymorphic in all populations examined. Con-
sistent with how this genetic variation has been analyzed
previously [13,49], the alleles were classified as short
(<16), medium (16–23), and long (>23) repeats. The dis-
tribution of the length of the repeat is displayed in Figure
1, and frequencies of the allele are presented in Table 1.
The medium length allele accounted for >50% of total
alleles in all populations with the exception of Asian
Americans, where it was 39.4%.
A previous report showed that the TLR2 SNP Arg753Gln
is absent in Urat and Urim speakers from Papua New
Guinea [50]. Therefore, this SNP was not tested here.
Arg753Gln was also absent in Kenyans but present in
North Americans, consistent with previous reports [51].
TLR4, TLR9, and MAL SNP allele frequencies
The two TLR4 SNPs examined in this study are absent in
the Urat and Urim linguistic groups in Papua New Guinea
Table 1: TLR2, 4, 9, and MAL mutant allele frequencies in various populations
PNG Kenya North America
Gene Mutant allele lowlands lowlands Highlands African Caucasian Asian
TLR2
Δ22 0.131I 0.298 0.326II 0.215 0.131 0.256VI
GTS 0.091 0.082 0.145 0.111 0.036 0.212
GTM 0.522I 0.799 0.761 0.721 0.583 0.394VI
GTL 0.387 0.120 0.094 0.168 0.381 0.394
Arg753Gln 0.000V 0.000 0.000 0.011 0.038 0.000
TLR4
Asp299Gly 0.000V 0.071III 0.054II 0.131 0.086 0.042
Thr399Ile 0.000V 0.015 0.007 0.028 0.095 0.036
TLR9
-1486T/C 0.371I 0.270 0.25IV 0.343 0.340 0.361
-1237T/C 0.000 0.351 0.362 0.337 0.130 0.066
1174G/A 0.624I 0.403 0.481II 0.341 0.525 0.590
MAL
Ser180Leu 0.149 0.000 0.025 0.056 0.160 0.060VI
GTS < 16 repeats, GTM 16–23 repeats, GTL > 23 repeats.
Ip < 0.05, compared with Kenyan lowlands
IIp < 0.05 compared to African Americans
IIIp = 0.062 compared to African Americans
IVp = 0.067 compared to African Americans
Vtested previously [50]
VIp < .005 compared to PNGPage 4 of 10
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Asp299Gly and Thr399Ile amino acid mutations were
present at frequencies that were not statistically different
for the Kenyans residing in the malaria holoendemic and
episodic transmission areas (range 0.7–7.1%). With the
exception of -1237C in Papua New Guineans and Asian
Americans, all TLR9 SNPs were present at a frequency
greater than 10%. Both -1486T/C and 1174G/A were
more common in Papua New Guinea compared to the
Kenya holoendemic site (p = 0.026 and p < 0.001, respec-
tively). There were no significant differences in TLR9 SNP
frequencies associated with different malaria exposures in
Kenya. The MAL 180 mutant allele was most common in
Papua New Guineans (14.9%). In contrast, this allele was
completely absent in the holoendemic Kenyan transmis-
sion site, and present in only 2.5% in the episodic trans-
mission site.
Frequencies of TLR2, TLR 4, TLR9, and MAL genotypes
Table 2 shows the genotype frequencies for TLR2 Δ22,
TLR4, TLR9, and the MAL polymorphisms. All three TLR2
Δ22 genotypes were found in all populations, and were in
Hardy-Weinberg equilibrium. The TLR4, TLR9, and MAL
SNPs were in Hardy-Weinberg equilibrium in both Kenya
and Papua New Guinea. In contrast to Papua New Guine-
ans where -1237C was absent, this allele was present in
Asian Americans, for whom there were fewer heterozy-
gotes than expected (p = 0.022). The MAL genotypes were
in Hardy-Weinberg equilibrium in all populations except
in African Americans, where there was a deficit of hetero-
zygosity (p = 0.02).
Inferred haplotypes and linkage disequilibrium
Statistically inferred haplotypes for TLR2, TLR4, and TLR9
are described in Table 3. Of six possible TLR2 haplotype
combinations, all were present in Papua New Guineans
and North Americans. The deletion allele did not co-seg-
regate with any of the GT repeat length alleles, as deter-
mined in linkage disequilibrium analysis where two
polymorphisms were considered in linkage disequilib-
rium if the values for D' and r2 were >0.9 (data not
shown). The Asp299Gly and Thr399Ile SNPs in the TLR4
gene commonly co-segregated in Caucasian Americans.
Consistent with these data, the two polymorphisms were
in linkage disequilibrium as measured by D' and r2 (data
not shown). In Kenya, the TLR4 mutations co-segregated
less frequently, and the Gly-Thr haplotype was present at
5–6% frequency in both the episodic transmission and
holoendemic study sites. This haplotype was also found
in African Americans and Asian Americans. There was no
linkage disequilibrium between Asp299Gly and
Thr399Ile in the Kenyans, African Americans, or Asians
Americans (data not shown). The most common TLR9
haplotypes were CTG and TTA, except in Kenyans and
African Americans, where TCG and TTA were the most
common. There were fewer TLR9 haplotypes present in
Papua New Guineans compared to the other populations,
largely due to the absence of the -1237 allele. There was
linkage disequilibrium between all TLR9 SNP pairs
present in Papua New Guineans (data not shown). This
linkage disequilibrium was absent in the Kenyan and
Asian American populations.
Discussion
There is compelling evidence that evolution of the human
genome has involved selective pressure exerted by micro-
bial pathogens. Perhaps one of the best characterized
examples of this natural selection process is historical
exposure to falciparum malaria and its' association with
the β-globin SNP underlying the haemoglobin S sickle cell
trait. The frequency of this mutant allele (and other β-
globin variants such as haemoglobin C) is greater than
25% in populations in Sub-Saharan Africa where it has
been observed to mediate a strong protective effect against
severe malaria [52]. Data reported here provide informa-
tion relevant to the growing interest in understanding
how innate immunity may contribute to malaria suscepti-
bility. Information on the genetics of innate immunity
should help define the basis of individual and population
variation in susceptibility to malaria pathogenesis and
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Table 2: TLR2, 4, 9, and MAL genotypes in various populations
PNG Kenya North America
PolymorphismI genotype lowlands lowlands highlands African Caucasian Asian
TLR2 Δ22 WW 253(76) 41(49) 33(48) 58(62) 64(76) 49(58)
WDII 73(22) 36(43) 27(39) 30(32) 18(21) 27(32)
DD 7(2) 7(8) 9(13) 5(5) 2(2) 8(10)
TLR4 Asp299Gly Asp/Asp 906(100)IV 78(86) 66(89) 65(74) 67(83) 76(92)
Asp/Gly 0 13(14) 8(11) 23(26) 14(17) 7(8)
TLR4 Thr399Ile Thr/Thr 906(100)IV 64(97) 69(99) 84(94) 64(81) 77(93)
Thr/Ile 0 2(3) 1(1) 5(6) 15(19) 6(7)
TLR9 -1486 TT 137(41) 47(54) 41(54) 37(42) 36(44) 34(41)
CT 146(44) 33(38) 32(42) 43(48) 35(43) 38(46)
CC 51(15) 7(8) 3(4) 9(10) 10(12) 11(13)
TLR9 -1237 TT 334(100) 39(45) 29(38) 36(40) 61(75) 74(89)
CT 0 35(40) 39(51) 46(52) 19(23) 7(8)III
CC 0 13(15) 8(11) 7(8) 1(1) 2(2)
TLR9 1174 GG 53(16) 29(32) 17(22) 35(43) 22(27) 14(17)
GA 147(44) 47(53) 47(60) 38(46) 33(41) 40(48)
AA 136(41) 12(14) 14(18) 9(11) 26(32) 29(35)
MAL 180 Ser/Ser 254(73) 89(100) 75(95) 82(91) 53(68) 73(88)
Ser/Leu 81(23) 0 4(5) 6(7)III 25(32) 10(12)
Leu/Leu 11(3) 0 0 2(2) 0 0
Ino.(%)
IID is deletion allele, W is wild type/insertion allele
IIIp < .05, Hardy-Weinberg test of equilibrium, deficit of heterozygosity
IVgenotyped previously [50]
Table 3: TLR2, TLR4, and TLR9 haplotypes in various populations
PNG Kenya North America
Gene Haplotype lowlands lowlands highlands African Caucasian Asian
TLR2I
DL 0.029 0.000 0.000 0.000 0.000 0.086
DM 0.011 0.258 0.239 0.164 0.099 0.105
DS 0.093 0.041 0.092 0.051 0.033 0.063
WL 0.355 0.110 0.100 0.161 0.388 0.300
WM 0.509 0.559 0.515 0.572 0.480 0.293
WS 0.003 0.033 0.054 0.052 0.000 0.154
TLR4II
Asp-Thr 1IV 0.924 0.943 0.869 0.905 0.952
Gly-Ile 0 0.015 0.007 0.028 0.089 0.030
Gly-Thr 0 0.061 0.050 0.102 0.000 0.012
Asp-Ile 0 0.000 0.000 0.000 0.006 0.006
TLR9III
C C A 0.000 0.006 0.007 0.000 0.000 0.000
C C G 0.000 0.075 0.099 0.092 0.000 0.011
C T A 0.003 0.000 0.011 0.018 0.000 0.007
C T G 0.368 0.205 0.136 0.244 0.353 0.343
T C G 0.000 0.266 0.254 0.256 0.115 0.055
T T A 0.625 0.396 0.455 0.324 0.526 0.584
T T G 0.005 0.051 0.037 0.066 0.006 0.000
IΔ22-GTn haplotypes
D is deletion allele, W is wild type
S < 16 repeats, M 16–23 repeats, L > 23 repeats.
IIFirst amino acid is 299, second amino acid is 399
IIIFirst nucleotide is -1486, second is -1237, and third is 1174.
IVGenotyped previously [50]
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vants, and treatments to fight this infectious disease.
This study focused on TLR2, TLR4, TLR9 and MAL because
these genes have been implicated in human malaria
pathogenesis. Evidence for this includes in vitro experi-
ments in which engagement of the immune receptor by
putative malaria toxins and activation of downstream sig-
naling pathways lead to production of pro-inflammatory
cytokines [5,27,28], and from case-control studies in
which the frequencies of selected polymorphisms among
individuals with severe malaria illness are compared with
those of ethnically and age-matched residents with
asymptomatic malaria [4,6]. The results presented here
suggest that none of the TLR or MAL polymorphisms
examined have been under strong selective pressure by
malaria. Although the protective haemoglobin S and
G6PD polymorphisms are significantly more common in
Kenyan residents of the malaria holoendemic area com-
pared to residents of the nearby episodic low transmission
area [39], statistically significant differences in mutant
allele frequencies of the TLR or MAL polymorphisms were
not detected. A notable finding in the Papua New Guinea
population is concerned with the MAL SNP that confers a
Ser→Leu amino acid change. The mutation abrogates
downstream signaling following ligand engagement of
TLR2 and TLR4. The frequency of the mutant allele in the
Papua New Guinea population was high (14.9%, see
Table 1) compared to the other populations. Moreover,
identification of homozygous individuals for the mutant
Leu allele (11 of 254 individuals, see Table 2) is of poten-
tial interest since previous studies have suggested that het-
erozygosity affords protection against not only malaria
but also bacterial infections. Homozygosity for this allele
has not been observed in African populations (e.g. Khor,
et al [6] reported no homozygous individuals among the
4902 West and East Africans genotyped in their study.)
Third, all of the polymorphisms in malaria endemic pop-
ulations studied here were in Hardy-Weinberg equilib-
rium, suggesting that selective pressure by malaria (or
other population-wide effects such as bacterial infection,
starvation, population size, non-random mating, etc), has
not affected the frequency and distribution of the allele.
Additionally, these alleles followed the Neutral Theory as
determined by a p-value < 0.05 for the Ewens-Watterson
test of homozygosity. For the polymorphisms examined
in these study populations, the frequency of observed
homozygotes was not significantly different than the
homozygote frequency expected under the Neutral The-
ory. This suggests that genetic drift rather than natural
selection, by malaria or any other agent, has been more
significant in determining these allele frequencies.
The lack of difference in the frequency of these polymor-
phisms among populations with varying levels of malaria
endemicity may be because these innate immune path-
ways truly do not alter susceptibility to severe malaria.
However, it is important to recognize alternative explana-
tions. The number of individuals sampled may be insuffi-
cient to detect statistically small but biologically
meaningful differences. Whereas MAL Ser180Leu and the
TLR4 SNPs in other populations have respectively, been
associated with protection and susceptibility to malaria,
these associations may not exist in the Kenyan or Papua
New Guinean populations examined here. For example,
HLA-B*5301 and HLA-DRB1*1302 were associated with
resistance to severe malaria in Gambia [53], whereas this
association was not found in Kenya [54]. TNF and ICAM-
1 polymorphisms and their association with malaria sus-
ceptibility has also been inconsistent across various pop-
ulations (reviewed in [52]). Other counter-selective forces
in these populations also may be acting to limit the spread
of the polymorphisms in the genes studied here. Polymor-
phisms that are protective against malaria may increase
the risk of non-malarial infectious diseases. For example,
recently it was demonstrated that Duffy blood group-neg-
ativity, which confers complete protection from blood
stage P. vivax in Africans [55], increases the risk of HIV
infection in African Americans and may also contribute to
the burden of HIV infection in Africa [56]. Because TLRs
and their downstream adaptor proteins are critical in the
responses to different pathogens, it is likely that similarly
complex selective pressures act on these genes.
This study is the first to describe the TLR2 5' untranslated
polymorphisms in Kenyans and Papua New Guineans
from malaria endemic areas. These polymorphisms pre-
sumably affect transcription and/or translation. The Δ22
polymorphism is located in the first untranslated exon of
TLR2, approximately 60 bp downstream of an NF-kB site
critical for chromatin remodeling and binding of tran-
scription factors [57]. The in vitro phenotypes of Δ22 and
GTn need to be investigated more thoroughly to deter-
mine their effect on mRNA transcription and/or transla-
tion. Although these polymorphisms have not been
studied in malaria case-control studies, TLR2 is poten-
tially involved in the pathogenesis of malaria because of
its putative role as a receptor for P. falciparum-derived GPI
[5].
Future studies with larger sample sizes, additional SNPs,
and other genetic loci are needed to determine more com-
pletely whether falciparum malaria has been involved in
natural selection of genes that regulate innate immunity
in humans. Advances in analytic and molecular tools such
as tagged SNPs, such as those now available in the Inter-
national HapMap project, also make it possible to identify
signatures of natural selection in these and other genetic
loci without a priori knowledge of their biologic function
and contribution to malaria pathogenesis [58].Page 7 of 10
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The goal of this study was to identify TLR and TLR adaptor
polymorphisms under selective pressure by malaria. The
data suggest that history of malaria exposure of the two
Kenyan populations has not been involved in selection of
TLR2, 4, and 9 or MAL polymorphisms. Case-control stud-
ies comparing the frequencies of these polymorphisms
among individuals with severe malaria with those with
asymptomatic malaria infection need to be conducted to
define more completely the potential role of these innate
immune genes in human malaria pathogenesis.
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